RepliCel Life Sciences
Company Details
Status: Public
Employees: 11-50
Location:
Vancouver, Canada
Type:
sample
Technology:
sample
sample
sample
sample
sample
About: RepliCel Life Sciences Inc. is leading a revolution in the development of products for sports medicine and aesthetics.
We are a regenerative medicine company developing innovative, clinical-stage technologies for unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.
RepliCel is currently involved in three clinical development programs: RCT-01 for treatment of Achilles tendinosis, RCS-01 for skin rejuvenation, and RCH-01 for treatment of Androgenic Alopecia.
In Asia, RCH-01 is the subject of a co-development partnership with cosmetics and skincare giant Shiseido Company, Limited. Shiseido is currently funding a clinical study for the treatment of male and female pattern baldness (androgenic alopecia) in Japan with data anticipated in late 2018.
RepliCel's nearest-term commercial asset is its next-generation dermal injector, RCI-02 which represents a medical device bringing unparalleled precision and consistency to dermal injections including shallow, even dispersion of dermal fillers for fine wrinkles. RCI-02 also promises to obviate the need for local anesthetic injections due to its patented skin-numbing element embedded in the device.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
RepliCel Life Sciences | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.